

1. **Ylinen J**, Kankainen T, Kautiainen H, Rezasoltani A, Kuukkanen T, **Häkkinen A**. Effect of stretching on hamstring muscle compliance. *J Rehabil Med* 2009 Jan;41(1):80-4.
2. Borg H, **Kiviranta I**, Anttila E, Hakkinen K, **Ylinen J**, Kautiainen H, **Hakkinen A**. External rotation strength deficit after hip resurfacing surgery. *Disabil Rehabil* 2009;31;865-70.
3. **Salo PK**, **Häkkinen AH**, Kautiainen H, **Ylinen JJ**. Quantifying the effect of age on passive range of motion of the cervical spine in healthy working-age women. *J Orthop Sports Phys Ther.* 2009 Jun;39(6):478-83.
4. Uutela T, **Hannonen P**, Kautiainen H, Hakala M, Paananen ML, **Häkkinen A**. Positive treatment response improves the health-related quality of life of patients with early rheumatoid arthritis. *Clin Exp Rheumatol.* 2009 Jan-Feb;27(1):108-11.
5. Sillanpää E, Laaksonen DE, **Häkkinen A**, Karavirta L, Jensen B, Kraemer WJ, **Nyman K**, Häkkinen K. Body composition, fitness, and metabolic health during strength and endurance training and their combination in middle-aged and older women. *Eur J Appl Physiol.* 2009 May;106(2):285-96.
6. Multanen J, Rauvala E, Lammentausta E, Ojala R, **Kiviranta I**, **Häkkinen A**, Nieminen MT, Heinonen A. Reproducibility of imaging human knee cartilage by delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) at 1.5 Tesla. *Osteoarthritis Cartilage.* 2009 May;17(5):559-64.
7. Karavirta L, Tulppo MP, Laaksonen DE, **Nyman K**, Laukkanen RT, Kinnunen H, **Häkkinen A**, Häkkinen K. Heart rate dynamics after combined endurance and strength training in older men. *Med Sci Sports Exerc.* 2009 Jul;41(7):1436-43.
8. Tomas-Carus P, Gusi N, **Häkkinen A**, Häkkinen K, Raimundo A, Ortega-Alonso A. Improvements of muscle strength predicted benefits in HRQOL and postural balance in women with fibromyalgia: an 8-month randomized controlled trial *Rheumatology (Oxford).* 2009 ;48:1147-57.
9. **Ylinen J**, Pikkarinen E. TULE-oireet voivat olla myös lääkkeen haittavaikutus. *Suomen Lääkärilehti* 2009;64:3682-86.
10. **Paltamaa J**, Knuutila S, Peurala S, Sjögren T, Suomela-Markkanen T, Heinonen A. Kelan kuntoutuksen piirissä olevien vaikeavammaisten kuntoutussuunnitelmissa on suuria puutteita. *Lääkärilehti* 2009;64:3853-60.
11. Karavirta L, **Häkkinen A**, Sillanpää E, García-López D, Kauhanen A, Haapasaari A, Alen M, Pakarinen A, Kraemer WJ, Izquierdo M, Gorostiaga E, Häkkinen K. Effects of combined endurance and strength training on muscle strength, power and hypertrophy in 40-67-year-old men. *Scand J Med Sci Sports.* 2009 Dec 18. [Epub ahead of print

12. **Häkkinen A, Arkela-Kautiainen M, Sokka T, Hannonen P**, Kautiainen H. Self-report functioning according to the ICF model in elderly patients with rheumatoid arthritis and in population controls using the multidimensional health assessment questionnaire. *J Rheumatol.* 2009 Feb;36(2):246-53.
13. **Häkkinen A**, Kukka A, **Onatsu T**, Järvenpää S, Heinonen A, Kyröläinen H, Tomas-Carus P, **Kallinen M**. Health-related quality of life and physical activity in persons at high risk for type 2 diabetes. *Disabil Rehabil.* 2009;31(10):799-805.
14. Sihvonen S, Kulmala J, **Kallinen M**, Alén M, **Kiviranta I**, Sipilä S. Postural balance and self-reported balance confidence in older adults with a hip fracture history. *Gerontology.* 2009;55(6):630-6.
15. Portegijs E, Rantanen T, **Kallinen M**, Heinonen A, Alén M, **Kiviranta I**, Sipilä S. Lower-limb pain, disease, and injury burden as determinants of muscle strength deficit after hip fracture. *J Bone Joint Surg Am.* 2009 Jul;91(7):1720-8.
16. Mänty M, Heinonen A, Leinonen R, Törmäkangas T, **Hirvensalo M, Kallinen M**, Sakari R, von Bonsdorff MB, Heikkinen E, Rantanen T. Long-term effect of physical activity counseling on mobility limitation among older people: a randomized controlled study. *J Gerontol A Biol Sci Med Sci.* 2009 Jan;64(1):83-9.
17. Rosqvist E, Heikkinen E, Lyyra TM, Hirvensalo M, **Kallinen M**, Leinonen R, Rasinaho M, Pakkala I, Rantanen T. Factors affecting the increased risk of physical inactivity among older people with depressive symptoms. *Scand J Med Sci Sports.* 2009 Jun;19(3):398-405.
18. Rosqvist E, **Aukee P, Kallinen M**. Lantiopohjalihasten omatoiminen harjoittelu: Käypä hoito-harjoitteluhjelman toteutettavuus virtsankarkailun hoidossa iäkkäillä naisilla. *Fysioterapia* 2009;56:35-40.
19. Koskinen S, Talo S, Hokkinen E-M; **Paltamaa J**, Musikka-Siirtola M. Neljän elämänlaatumittarin sisältöanalyysi ICF-luokituksen viitekehityksessä. *Sosiaalilääketieteellinen aikakauslehti* 2009;46(3):196-207.
20. Rosqvist E, Harri-Lehtonen O, Airaksinen T, Ylinen A, **Kallinen M**. CP- vammaisen toimintakyky heikkenee jo nuorena aikuisena. *Lääkärilehti* 2009;48:4147-4150.
21. Puolakka K, Kautiainen H, **Hannonen P**, Korpela M, Hakala M, Luukkainen R, Vuori K, Blåfield H, Leirisalo-Repo M, for the FIN-RACo Trial Group: Use of the Stanford health assessment questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis. *Scand J Rheumatol* 2009;38:96-103.
22. **Hannonen P**: Onko fibromyalgian diagnosointi tarpeellista? *Duodecim* 2009;125:521-6.
23. Mäkinen H, **Hannonen P**: How to assess patients with rheumatoid arthritis and concomitant fibromyalgia? *The journal of rheumatology* 2009;36:9-10.
24. Puolakka K, Kautiainen H, Möttönen T, **Hannonen P**, Korpela M, Hakala M, Viikari-Jutnura E, Solovieva S, Arkela-Kautiainen M, Leirisalo-Repo M: A mismatch between

- self-reported physical work load and the HAQ: early identification of rheumatoid arthritis patients at risk for loss of work productivity. *Clinical and Experimental Rheumatology* 2009;27:422-429.
25. Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, **Hannonen P**, Leirisalo-Repo M: Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. *Scand J Rheumatol* 2009;38:323-327.
26. Hakala M, **Hannonen P**, Helve T, Korpela M, Mattila K, Möttönen T, Varis T: Nivelreuma. *Duodecim* 2009;125:2131-2.
27. **Sokka T**, Toloza S, Cutolo M, Kautiainen H, Mäkinen H et al: Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. *Arthritis Res Ther* 2009;11.
28. **Sokka T**, Pincus T: Rheumatoid arthritis: strategy more important than agent. *The Lancet* 2009;374:430-431.
29. Hee Rho Y, Solus J, **Sokka T**, Oeser A, Chung C, Gebretsadik T, Shintani A, Pincus T, Stein M: Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. *Arthritis & Rheumatism* 2009;60:1906-1914.
30. **Sokka T**, **Mäkinen H**: An excellent example of an early arthritis clinic – what is its clinical value? *J Rheumatol* 2009;36:1355-1356.
31. Mäkinen H, **Sokka T**: Nivelreuman aktiivisuusmittareiden hyödyntäminen potilaan hoidossa. *Suomen Lääkärilehti* 2009;64:2183.
32. Koskinen E, **Hannonen P**, **Sokka T**: Palindromic rheumatism: Longterm outcomes of 60 patients diagnoses in 1967-84. *J Rheumatol* 2009;36:1873-5.
33. Abelson B, **Sokka T**, Pincus T: Declines in erythrocyte sedimentation rates in patients with rheumatoid arthritis over the second half of the 20th century. *The Journal of Rheumatology* 2009;36:8:1596.
34. Khan NA, Yazici Y, Calvo-Alen J, Dadoniene J, Gossec L, Hansen TM, Huisman M, Kalliokorm R, Muller R, Liveborn M, Oding R, Luchikhina E, Naranjo A, Rexhepi S, Taylor P, Tlustochowich W, Tsirogianni A, **Sokka T** on behalf of QUEST-RA group: Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. *J Rheumatol* 2009;36:2435-42.
35. Pincus T, Swearingen CJ, Luta G, **Sokka T**: Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial. *Ann Rheum Dis* 2009;68:1715-1720.
36. **Sokka T**, Kautiainen H, Pincus T, Toloza S et al: Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. *Ann Rheum Dis* 2009;68:1666-1672

37. **Saltevo J, Kautiainen H, Vanhala M:** Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. *Gender Medicine* 2009;6:463
38. Ahonen T, **Saltevo J**, Laakso M, **Kautiainen H**, Kumpusalo E, **Vanhala M:** Gender differences relating to metabolic syndrome and proinflammation in Finnish subjects with elevated blood pressure. *Mediator of Inflammation* 2009
39. Mustonen P, Halinen M, **Melin J**, Mustonen P, Niemi T, Puuru M, Lassila R: Sydänpotilaan antitromboottinen lääkitys leikkausten ja pientoimenpiteiden yhteydessä. *Duodecim* 2009;125:47-58.
40. **Forslund T, Koistinen A, Miettinen M:** Experience with cinacalcet of secondary hyperparathyroidism in patients with chronic kidney disease stage III and IV. *Clinical Medicine: Therapeutics* 2009;1:801-808.
41. **Karppi P, Rummukainen M, Jakobsson A, Matsinen M:** Oheistus lisäsi käsihuuhteen ja vähensi antibioottien käyttöä vanhusten hoitopaikoissa. *Suomen Lääkärilehti* 2009;64:501-503.
42. Hiltunen-Back E, Ruutu P, **Kautiainen H**, Ådahl L, Savolainen R, Paavonen J, Reunala T: Toistuvat sukupuolitaudit ovat yleisiä. *Suomen Lääkärilehti* 2009;37:2999.
43. Kautio A-L, Haanpää M, Leminen A, Kalso E, **Kautiainen H**, Saarto T: Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. *Anticancer Res* 2009;29:2601-6.
44. Vanto T, Isolauri E, Jartti T, Kaila M, Korhonen K, Komulainen J, Mäkelä M, Mäkinen-Kiljunen S, **Poikonen S**, Savilahti E, Schwab U, Voutilainen H: Lasten ruoka-allergia. *Duodecim* 2009;125:1992-3.
45. Järvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomäki P, Aaltonen LA, **Mecklin J-P:** Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. *J Clin Oncol* 2009;27:4793-4797.
46. Silvennoinen M, **Mecklin J-P**, Saariluoma P, Antikainen T: Expertise and skill in minimally invasive surgery. *Scandinavian Journal of Surgery* 2009;98:209-214.
47. Gylling A, Ridanpää M, Vierimaa O, Aittomäki K, Avela K, Kääriäinen H, Laivuori H, Pöyhönen M, Sallinen S-L, Wallgren-Pettersson C, Järvinen HJ, **Mecklin J-P**, Peltomäki P: Large genomic rearrangements and germline epimutations in Lynch syndrome. *Int J Cancer* 2009;124:2333-2340.
48. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, Björklund M, Wei G, Yan J, Niittymäki I, **Mecklin J-P** et al: The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhance Wnt signaling. *Nature Genetics* 2009;41:885-
49. Nieminen T, Gylling An, Abdel-Rahman W, Nuorva K, Aarnio M, Renkonen-Sinisalo L, Järvinen HJ, **Mecklin J-P**, Bützow R, Peltomäki P: Molecular analysis of endometrial

- tumorigenesis: importance of complex hyperplasia regardless of atypia. *Clin Cancer Res* 2009;15:5772-83.
50. Vasara A, Konttinen Y, Peterson L, Lindahl A, **Kiviranta I**: Persisting high levels of synovial fluid markers after cartilage repair. *Clin Orthop Relat Res* 2009;467:267-272.
51. Rieppo J, Hyttinen MM, Halmesmäki E, Ruotsalainen H, Vasara A, **Kiviranta I**, Jurvelin JS, Helminen HJ: Changes in spatial collagen content and collagen network architecture in porcine articular cartilage during growth and maturation. *Osteoarthritis and Cartilage* 2009;17:448-455.
52. Kiviranta P, Lammentausta E, Töyräs J, Nieminen HJ, Julkunen P, **Kiviranta I**, Jurvelin JS: Differences in acoustic properties of intact and degenerated human patellar cartilage during compression. *Ultrasound in Med & Biol* 2009;35:1367-1375.
53. **Lönnerros E**, Kautiainen H, Sund R, **Karppi P**, Hartikainen S, **Kiviranta I**, Sulkava R: Utilization of inpatient care before and after hip fracture: a population-based study. *Osteoporos Int* 2009;20:879-886.
54. **Murtola TJ**, Tammela TLJ, Määttä L, Ala-opas M, Stenman UH, Auvinen A: Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish prostate cancer screening trial. *British Journal of Cancer* 2009;101:843-8.
55. **Murtola TJ**, Pennanen P, Syväälä H, Bläuer M, Ylikomi T, Tammela T: Effects of Simvastatin, acetylsalicylic acid and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. *Prostate* 2009;69:1017-23.
56. Kautio AL, Haanpää M, Leminen A, Kalso E, **Kautiainen H**, Saaarto T: Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. *Anticancer Res* 2009;29:2601-6.
57. Ovaskainen Y, Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E, **Vanhala M**: Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males. *Psychiatry res* 2009;15:167;73-9.
58. **Vanhala M**, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E, Koponen H: Depressive symptoms predispose females to metabolic syndrome: a 7-year follow-up study. *Acta psychiatrica scandinavica* 2009;119:137-142.
59. **Nissinen A**, Stranden P, Mylly R, Takkinen J, Björkman Y, Leinikki P, Siitonen A: Point-of-care testing of group A streptococcal antigen: performance evaluated by external quality assessment. *Eur J Clin Microbiol Infect Dis* 2009;28:17-20.
60. Sihvonen LA, Haukka K, Kuusi M, Virtanen MJ, Siitonen A, YE study group (appendix. **Nissanen A**). *Yersinia enterocolitica* and *Y. enterocolitica*-like species in clinical stool specimens of humans: identification and prevalence of bio/serotypes in Finland. *Eur J Clin Microbiol Infect Dis* 2009;28:757-765.

61. **Rummukainen M, Jakobsson A, Karppi P**, Kautiainen H, Lyytikäinen O: Promoting hand hygiene and prudent use of antimicrobials in long-term care facilities. *Am J Infect Control* 2009;37:168-71.
62. Pincus T, Callahan LF, **Sokka T**. A Standard Protocol to Evaluate Rheumatoid Arthritis (SPERA) for efficient capture of essential data from a patient and a health professional in a uniform "scientific" format. *Rheum Dis Clin North Am.* 2009 Nov;35(4):843-50, xi.
63. Pincus T, **Sokka T**. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. *Rheum Dis Clin North Am.* 2009 Nov;35(4):731-4, vi-vii.
64. Yazici Y, **Sokka T**, Pincus T. Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. *Rheum Dis Clin North Am.* 2009 Nov;35(4):723-9, vi.
65. **Sokka T**, Pincus T. Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. *Rheum Dis Clin North Am.* 2009 Nov;35(4):713-22, v-vi.
66. Pincus T, Yazici Y, **Sokka T**. Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. *Rheum Dis Clin North Am.* 2009 Nov;35(4):687-97, v.
67. Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, **Sokka T**, Pincus T, Raggi P, Gebretsadik T, Shintani A, Stein CM. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. *Arthritis Rheum.* 2009 Nov 15;61(11):1580-5.
68. **Sokka T**. Influence of gender on the symptoms and severity of rheumatoid arthritis: do women suffer more? *Int J Clin Rheumatol* 2009;4(3):245-247
69. Liu Z, **Sokka T**, Maas K, Olsen N, Aune TM. Prediction of Disease Severity in Patients with Early Rheumatoid Arthritis by Gene Expression Profiling. *Human Genomics and Proteomics*, vol 2009, Article ID 484351, 10 pages, 2009. doi:10.4061/2009/484351
70. Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadello S, Carmona L, Daurès JP, de Wit M, Dijkmans BA, Englbrecht M, Gunendi Z, Heiberg T, Kirwan JR, Mola EM, Matucci-Cerinic M, Otsa K, Schett G, **Sokka T**, Wells GA, Aanerud GJ, Celano A, Dudkin A, Hernandez C, Koutsogianni K, Akca FN, Petre AM, Richards P, Scholte-Voshaar M, Von Krause G, Kvien TK. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. *Ann Rheum Dis.* 2009 Nov;68(11):1680-5. Epub 2008 Dec 3.
71. Pincus T, **Sokka T**. "Keep It Simple Stupid": MDHAQ function, Pain, Global, and RAPID3 Quantitative Scores to Improve and Document Quality of Rheumatologic Care. *J Rheumatol.* 2009 Jun;36(6):1099-100.
72. Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, Seldin MF, Criswell LA, Plenge RM, Holers VM, Mikuls TR, **Sokka T**, Moreland LW, Bridges SL Jr, Xie G, Begovich AB, Siminovitch KA. REL, encoding a member of the NF-kappaB family

- of transcription factors, is a newly defined risk locus for rheumatoid arthritis. *Nat Genet.* 2009 Jun 7. [Epub ahead of print]
73. **Sokka T**, Pincus T. Erythrocyte Sedimentation Rate, C-Reactive Protein, or Rheumatoid Factor are normal at presentation in 35-45% of patients with rheumatoid arthritis seen between 1980 and 2004: Analyses from Finland and the United States. *J Rheumatol* 2009 Jul;36(7):1387-90.
74. **Sokka T**. Long-term outcomes of rheumatoid arthritis. *Curr Opin Rheumatol* 2009;21:284-90.
75. **Sokka T**, Mäkinen H. Drug management of early rheumatoid arthritis - 2008. *Best Pract Res Clin Rheumatol.* 2009 Feb;23(1):93-102.
76. **Murtola T**: Prostate cancer incidence among men using statins, finasteride or antidiabetic drugs. Doctoral dissertation Tampere: Tampereen yliopistopaino oy 2009. Osajulkaisuväitöskirja
77. **Virkkunen J**, Venermo M, Saarinen J, Salenius J: Predictors for the immediate and long-term outcome of a vascular surgical procedure. *Scandinavian Journal of Surgery* 2009;98:164-168.
78. **Kellokumpu I**: Lantionpohjan toiminnallisten häiriöiden ja laskeumien hoito. *Duodecim* 2009;125:185-6.
79. **Kairaluoma M, Aukee P, Elomaa E**: Lantionpohjan toimintaan liittyvät häiriöt ja niiden diagnostiikka. *Duodecim* 2009;125:189-96.
80. **Kairaluoma M**: Toiminnallinen ulostamisvaikeusoireyhtymä. *Duodecim* 2009;125:221-5.
81. Salmela S, Poskiparta M, Kasila K, Vähäsarja K, **Vanhala M**: Transtheoretical model-based dietary interventions in primary care: a review of the evidence in diabetes. *Health Education Research* 2009;24:237-252.
82. Avela K, **Alen R**, Huttunen M, **Pärssinen O**: Megalocornea – Urticaria pigmentosa syndrome – a new syndrome? *EJMG* 2009;52:430-2.
83. Strengell T, Uhari M, Tarkka R, Uusimaa J, **Alen R**, Lautala P, Rantala H: Antipyretic agents for preventing recurrences of febrile seizures. *Arch Pediatr Adolesc Med* 2009;163:799-804.
84. Decramer M, Cell B, Kesten S, Lysting T, Mehra A, Tashkin D for the UPLIFT investigators (**Venho KK**): Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. *The Lancet* 2009;374 (9696):1171-8 (selvitys monikeskustutkimukseen osallistumisesta annettu)
85. Talvinen K, Karra H, Hurme S, **Nykänen M, Nieminen A, Anttinen J, Kuopio T, Krongqvist P**: Securin promotes the identification of favourable outcome in invasive breast cancer. *British Journal of Cancer* 2009;101:1005-1010.

86. Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Griffiths DF, Lopez-Betran A, Kiuz G, Varma M, Montironi R: European Network of uropathology (**Kuopio T**) a novel mechanism for communication between pathologists. *Anal Quant Cytol Histol* 2009;31(2):90-5. (selvitys monikeskustutkimukseen osallistumisesta annettu)
87. **Miettinen MH**, Mäkelä SM, Ala-Houhala I, Huhtala HS, Kööbi T, Vaheri AI, Pastrnack AI, Pörsti IH, Mutonen JT: Tubular proteinuria and glomerular filtration 6 years after Puumala hantavirus-induced acute interstitial nephritis. *Nephron Clin Pract* 2009;112:115-120.
88. **Pikkarainen E**, Viikari J: Vähäestrogeniset ehkäisytabletit ja nuorten naisten luomassan kehitys. *Duodecim* 2009;125:335-6.
89. Lepäntalo M, Laurila K, Roth WD, **Rossi P**, Lavonen J, Mäkinen K, Manninen H, Ronsi P, Perälä J, Bergqvist D, Scandinavian ThruPass study group: PTFE bypass or thruPass for superficial femoral artery occlusion? A randomised controlled trial. *Eur J Vasc Endovasc Surg* 2009;37:578-84.
90. Rantalaiho V, Korpela M, **Hannonen P**, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T for the FIN-RACo Trial Group: The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time. *Arthritis & Rheumatism* 2009;60:1222-1231.
91. Kauppi MJ, Neva MH, Laiho K, Kautiainen H, Luukkainen R, Karjalainen A, **Hannonen PJ**, Leirisalo-Repo M, Korpela M, Ilva K, Möttönen T, for the FIN-RACo Trial Group: Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs. *J Rheumatol* 2009;36:273-8.
92. Axelin A, Salanterä S, **Kirjavainen J**, Lehtonen L: Oral glucose and parental holding preferable to opioid in pain management in preterm infants. *Clin J pain* 2009;25:138-45.
93. **Tuuliranta M**: Aikuisen nivustyrä pitäisi leikata paikallispuudutuksessa. *Duodecim* 2009;125:9-11.
94. Airaksinen O, Färkkilä M, **Hannonen P**: Tulehduskivun lääkehoito – meneekö lapsi pesuveden mukana? *Suomen Lääkärilehti* 2009;33:2586-2589.
95. Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, **Saltevo J**, Sane T, Välimäki M, Nuutila P: The clinical value of (18F)fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. *Endocrine-related Cancer* 2009;16:255-265.
96. Juurinen L, Tiikkainen M, **Saltevo J**, Nikkilä K, Lanki H, Leppävuori E, Kock T, Teikari-Myyrä T, Kauppinen-Mäkelin R, Kotronen A, Yki-Järvinen H: Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes. *Diabetic Medicine* 2009;26:409-415.



97. Groop PH, Thomas MC, Moran JL et al; **FinnDiane Study group\* Saltevo J:** The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. *Diabetes* 2009;58:1651-8. **Monikeskustutkimus:** J.Saltevon potilasaineisto 300 henkilöä + kommentointi käsikirjoitukseen.
98. Wadén J, Forsblom C, Thorn LM et al; **FinnDiane Study group\* Saltevo J:** Adult stature and diabetes complications in patients with type 1 diabetes: the FinnDiane Study and the diabetes control and complications trial. **Monikeskustutkimus:** J.Saltevon potilasaineisto 300 henkilöä + kommentointi käsikirjoitukseen.
99. Nymark M, Pussinen P, Tuomainen A, Forsblom C, Groop PH, Lehto M on behalf of the **FinnDiane Study Group \* Saltevo J:** Serum lipopolysaccharide activity is associated with the progression of kidney disease in Finnish patients with type 1 diabetes. *Diabetes care* 2009;9:1689-1693. **Monikeskustutkimus:** J.Saltevon potilasaineisto 50 henkilöä + kommentointi käsikirjoitukseen.
100. Rajamani K, Colman P, Ping LI, Best JD et al behalf of the **FIELD-study investigators \* Saltevo J:** Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. *The Lancet* 2009;373:1780-. **Monikeskustutkimus:** J. Saltevon potilasaineisto: 106 potilasta, aktiivinen osallistuminen tutkimusprosessiin ja kommentit käsikirjoitukseen.
101. Scott R, O'Brien R, Fulcher G et al on behalf of the fenofibrate intervention event lowering in diabetes (**FIELD**) **Study Investigators \* Saltevo J:** Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome. *Diabetes Care* 2009;32:493-498. **Monikeskustutkimus:** J. Saltevon potilasaineisto: 106 potilasta, aktiivinen osallistuminen tutkimusprosessiin ja kommentit käsikirjoitukseen
102. Tolonen N, Forsblom C, Thorn L et al to **FinnDiane Study Group \* Saltevo J:** Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes: *Diabetologia* 2009;52:2522-30. **Monikeskustutkimus:** J.Saltevo osallistui tutkimukseen 200 potilaan aineistolla + kommentit käsikirjoitukseen.
103. Eastell R, Black DM, Poonen S et al; **HORIZON Pivotal Fracture Trial \* Saltevo J:** Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. *J Clin Endocrinol Metab* 2009;94:3215-25. **Monikeskustutkimus:** J. Saltevo osallistui tutkimukseen 22 potilalla.
104. Home PD, Pocock SJ, Beck-Nielsen H et al;**RECORD Study Team\* Saltevo J:** Rosiglitazone evaluated for cardiovascular outcomes in oral agents combination therapy for type 2 diabetes (RECORD): multicenter, randomised, open-label trial. *The Lancet* 2009;373:2125-35. **Monikeskustutkimus:** J Saltevo osallistui tutkimukseen 25 tutkimuspotilaalla.
105. Simen-Kapeu A, La Ruche G, Kataja V, **Yliskoski M**, Bergeron C, Horo A, Syrjänen K, Saarikoski S, Lehtinen M, Dabis F, Sasco AJ: Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous

intraepithelial lesions in two countries (Cote d'Ivoire and Finland) with different tobacco exposure. *Cancer Causes Control* 2009;20:163-70.

106. Heliövaara-Peippo S, Halmesmäki K, Hurskainen R, Teperi J, Grenman S, Kivelä A, Kujansuu E, Tuppurainen M, Vuorma S, **Yliskoski M**, Paavonen J: The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower abdominal pain and back pain among women treated for menorrhagia: a five-year randomized controlled trial. *Acta Obstet Gynecol Scand* 2009;88:1389-96.
107. **Väitöskirjatyö:** Lönnroos Eija: Hip fractures and medication-related falls in older people.